Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Elisabeth Rebber 1 Article
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
Mathias Lutz, Arik B. Schulze, Elisabeth Rebber, Stefanie Wiebe, Tarek Zoubi, Oliver M. Grauer, Torsten Keßler, Andrea Kerkhoff, Georg Lenz, Wolfgang E. Berdel
Cancer Res Treat. 2017;49(2):548-552.   Published online July 12, 2016
DOI: https://doi.org/10.4143/crt.2016.110
AbstractAbstract PDFPubReaderePub
Progressive multifocal leukoencephalopathy (PML) is a devastating neurological disease observed nearly exclusively in immunocompromised patients. Recently, the introduction of monoclonal antibodies significantly inhibiting the immune system such as rituximab has led to an increase in PML cases. Although rituximab-based immunochemotherapy remains the standard of treatment for chronic lymphocytic leukemia (CLL), the importance of Bruton’s tyrosine kinase inhibitors such as ibrutinib is steadily increasing. However, long-term experiences regarding possible side effects of these new substances are rare. Here, we report the development of eventually fatal PML possibly associated with ibrutinib therapy for CLL after multiple prior treatment lines, including rituximab. To the best of our knowledge, this is the first study to report such findings. Since the last course of rituximab was applied over 3 years ago, it is conceivable that the strong B cell inhibition by ibrutinib led to PML. With increased awareness of this potential side effect, further clinical studies are certainly warranted to evaluate this possible association.

Citations

Citations to this article as recorded by  
  • Progressive Multifocal Leukoencephalopathy in a Patient with Multifocal Neurological Manifestations Caused by Solitary Brainstem Involvement
    Akito Funatsu, Kazuo Nakamichi, Midori Araki, Tetsuya Fukumoto, Hideki Mine
    Internal Medicine.2023; 62(5): 787.     CrossRef
  • A case of progressive multifocal leukoencephalopathy in a post-kidney transplant patient with improvement after discontinuation of immunosuppressive drugs and combination therapy with mefloquine and mirtazapine
    Neri Sone, Hiroki Nishiwaki, Mayu Shimokawa, Keishu Kawanishi, Tsuyoshi Oshiro, Reiji Takami, Natsuki Taira, Masahito Amagasa, Shinya Omiya, Tadahide Maezumi, Yoko Nabeshima, Kazuo Nakamichi, Yoshiharu Miura, Fumihiko Koiwa
    Renal Replacement Therapy.2023;[Epub]     CrossRef
  • Progressive multifocal leukoencephalopathy in a patient with relapsed chronic lymphocytic leukemia treated with Ibrutinib
    Larissa Lane Cardoso Teixeira, Viviane Regina Hernandez Nunes, Guilherme Fleury Perini, Carolina Cristina Pellegrino Feres, Danielle Ovigli, Nelson Hamerschlak
    Hematology, Transfusion and Cell Therapy.2022; 44(3): 437.     CrossRef
  • Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia
    F. Tahir, J. Sy, S. Reddel, J. Trotman
    Leukemia & Lymphoma.2022; 63(6): 1464.     CrossRef
  • Progressive Multifocal Leukoencephalopathy Among Ibrutinib Treatment In Chronic Lymphocytic Leukemia
    Tuğba Çetintepe, Füsun Gediz, Işın Akyar, Lutfi Çetintepe, Ali Murat Koç
    Journal of Oncology Pharmacy Practice.2022; 28(5): 1249.     CrossRef
  • Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies
    Panagiotis T. Diamantopoulos, Konstantinos Kalopisis, Aikaterini Tsatsou, Athina Efthymiou, Nefeli Giannakopoulou, Sevastianos Hatzidavid, Nora‐Athina Viniou
    European Journal of Haematology.2022; 108(5): 359.     CrossRef
  • Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin’s lymphoma
    Thai Dang, Samir Macwan, Constantin A Dasanu
    Journal of Oncology Pharmacy Practice.2021; 27(6): 1534.     CrossRef
  • Therapeutic Experience of Progressive Multifocal Leukoencephalopathy Development during Ofatumumab Therapy for Chronic Lymphocytic Leukemia
    Yu Hashimoto, Takumi Tashiro, Ryosuke Ogawa, Kazuo Nakamichi, Masayuki Saijo, Takahisa Tateishi
    Internal Medicine.2021; 60(24): 3991.     CrossRef
  • Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
    Francesca Romana Mauro, Diana Giannarelli, Andrea Visentin, Gianluigi Reda, Paolo Sportoletti, Anna Maria Frustaci, Annalisa Chiarenza, Stefania Ciolli, Candida Vitale, Luca Laurenti, Lorenzo De Paoli, Roberta Murru, Massimo Gentile, Gian Matteo Rigolin,
    Cancers.2021; 13(13): 3240.     CrossRef
  • The Use of Antimalarial Drugs against Viral Infection
    Sarah D’Alessandro, Diletta Scaccabarozzi, Lucia Signorini, Federica Perego, Denise P. Ilboudo, Pasquale Ferrante, Serena Delbue
    Microorganisms.2020; 8(1): 85.     CrossRef
  • Ibrutinib-induced polyneuropathy: A case report
    Pınar Cömert, Murat Albayrak, Abdulkerim Yıldız, Osman Şahin, Hacer Berna Öztürk, Merih Reis Aras
    Journal of Oncology Pharmacy Practice.2020; 26(6): 1501.     CrossRef
  • JC Polyomavirus Infection Potentiated by Biologics
    Ashrit Multani, Dora Y. Ho
    Infectious Disease Clinics of North America.2020; 34(2): 359.     CrossRef
  • Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
    Phil‐Robin Tepasse, Wali Hafezi, Mathias Lutz, Joachim Kühn, Christian Wilms, Rainer Wiewrodt, Jan Sackarnd, Martin Keller, Hartmut H. Schmidt, Richard Vollenberg
    British Journal of Haematology.2020; 190(2): 185.     CrossRef
  • Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—A single institution experience and a review of literature
    Hira Shaikh, Ahmed Khattab, Muhammad S Faisal, Abhishek Chilkulwar, Mary Albrethsen, Santhosh Sadashiv, Salman Fazal
    Journal of Oncology Pharmacy Practice.2019; 25(5): 1265.     CrossRef
  • Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
    Georg Maschmeyer, Julien De Greef, Sibylle C. Mellinghoff, Annamaria Nosari, Anne Thiebaut-Bertrand, Anne Bergeron, Tomas Franquet, Nicole M. A. Blijlevens, Johan A. Maertens
    Leukemia.2019; 33(4): 844.     CrossRef
  • Neurological complications of new chemotherapy agents
    Alicia M Zukas, David Schiff
    Neuro-Oncology.2018; 20(1): 24.     CrossRef
  • Neuro-ophthalmic side effects of molecularly targeted cancer drugs
    M T Bhatti, A K S Salama
    Eye.2018; 32(2): 287.     CrossRef
  • ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
    M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi, J.M. Aguado
    Clinical Microbiology and Infection.2018; 24: S53.     CrossRef
  • Une hépatite inhabituelle chez un patient traité par obinutuzumab et ibrutinib
    S. Giorgiutti, M.P. Ledoux, E. Toussaint, Q. Maestraggi, C. Besch, M. Solis, R. Herbrecht, L.M. Fornecker
    La Revue de Médecine Interne.2018; 39: A202.     CrossRef
  • Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
    Ensi Voshtina, Huiya Huang, Renju Raj, Ehab Atallah
    Case Reports in Hematology.2018; 2018: 1.     CrossRef
  • Cryptococcus neoformansempyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature
    Christopher David Swan, Thomas Gottlieb
    BMJ Case Reports.2018; : bcr-2018-224786.     CrossRef
  • Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency
    S. A. Misbah
    Clinical & Experimental Immunology.2017; 188(3): 342.     CrossRef
  • T cell therapies for human polyomavirus diseases
    Sarah I. Davies, Pawel Muranski
    Cytotherapy.2017; 19(11): 1302.     CrossRef
  • Fludarabine/ibrutinib/rituximab

    Reactions Weekly.2017; 1657(1): 200.     CrossRef
  • The safety profile of monoclonal antibodies for chronic lymphocytic leukemia
    Anna Korycka-Wołowiec, Dariusz Wołowiec, Tadeusz Robak
    Expert Opinion on Drug Safety.2016; : 1.     CrossRef
  • 12,381 View
  • 497 Download
  • 26 Web of Science
  • 25 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP